(Q36258561)

13 August 2017

0 references

1 reference

title

Metabolic side effects of atypical antipsychotics in children: a literature review (English)

1 reference

13 August 2017

1 reference

2

Eric Fombonne

1 reference

13 August 2017

Valérie J Fedorowicz

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Journal of Psychopharmacology

13 August 2017

published in

1 reference

13 August 2017

volume

19

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

533-550

1 reference

Regulation of circulating leptin in humans

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Atypical antipsychotic drug use and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Hyperglycemia from olanzapine treatment in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Cholesterol and mental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Update and recommendations for the use of antipsychotics in early-onset psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Ziprasidone, a new atypical antipsychotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A case series of eight aggressive young children treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

The current epidemic of childhood obesity and its implications for future coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Childhood obesity: the health issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Association of olanzapine-induced weight gain with an increase in body fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Paediatric uses of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A prospective, open-label trial of olanzapine in adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Prescription of psychotropic medications to youths in office-based practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Effects of long-term treatment with antipsychotics on serum leptin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Antipsychotic medication: effects on regulation of glucose and lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Ziprasidone: a new atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Olanzapine-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Clozapine-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Open-label olanzapine treatment in five preadolescent children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Metabolic consequences of atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Characteristics of diabetic ketoacidosis in older versus younger adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Risperidone-associated weight gain in children and adolescents: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Clozapine in adolescent inpatients with acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Quetiapine treatment of children and adolescents with Tourette's disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A review of the effect of atypical antipsychotics on weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Olanzapine-induced destabilization of diabetes in the absence of weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Type 2 diabetes mellitus: the grand overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A 1-year open-label trial of olanzapine in school-age children with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Can diabetes mellitus be induced by medication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A study of quetiapine: efficacy and tolerability in psychotic adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Fatal olanzapine-induced ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Deaths from diabetic ketoacidosis after long-term clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Weight gain: side effect of atypical neuroleptics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

New-onset diabetes and ketoacidosis with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Effects of development on olanzapine-associated adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Elevated prolactin in pediatric patients on typical and atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Psychotropic practice patterns for youth: a 10-year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056543

21 January 2018

Identifiers

DOI

10.1177/0269881105056543

1 reference

13 August 2017

1 reference